RAF family kinases are RAS-activated switches that initiate signaling through the MAP kinase cascade to control cellular proliferation, differentiation and survival 1-3 . RAF activity is tightly regulated, and inappropriate activation is a frequent cause of cancer 4-6 . At present, the structural basis for RAF regulation is poorly understood. Here we describe autoinhibited and active state structures of full-length BRAF in complexes with MEK1 and a 14-3-3 dimer, determined using cryo electron microscopy (cryo-EM). A 4.1Å resolution cryo-EM reconstruction reveals an inactive BRAF/MEK1 complex restrained in a cradle formed by the 14-3-3 dimer, which binds the phosphorylated S365 and S729 sites that flank the BRAF kinase domain. The BRAF cysteine-rich domain (CRD) occupies a central position that stabilizes this assembly, but the adjacent RASbinding domain (RBD) is poorly ordered and peripheral. The 14-3-3 cradle maintains
activation segment were not (Extended Data Fig. 1c ). To eliminate potential heterogeneity due to phosphorylation of the MEK1 activation loop, we employed the MEK1 AA mutant for structure determination.
Cryo-EM imaging of the 192 kDa BRAF/MEK1 AA /14-3-3ε,ζ complex prepared in the presence of the ATP analog ATP-γS and MEK inhibitor GDC-0623 revealed well-dispersed particles with 2D class averages showing obvious secondary structure features (Extended Data Fig. 1d,e ). Approximately 8400 micrograph movies afforded single-particle reconstructions of this complex at a nominal resolution of 4.1Å (Fig. 1b, Extended Data Fig.  1f ), as detailed further in Methods and Extended Data Table 1 .
The cryo-EM map revealed a compact structure with inactive BRAF secured in a 14-3-3 "cradle" by extensive interactions with the 14-3-3 dimer (Fig. 1c ). The 14-3-3 engages both cognate sites in BRAF; the phosphorylated CR2 site (pS365) is bound in the recognition groove on one side of the 14-3-3 dimer, while the C-terminal (pS729) motif is bound in the groove on the opposite side of the dimer. The BRAF CRD domain is particularly central to the overall architecture of the complex. It contacts both subunits of the 14-3-3 dimer, both the pS365 and pS729 binding motifs, and the C-lobe of the BRAF kinase domain. The BRAF kinase domain is oriented with its active site facing away from the 14-3-3 domain, allowing it to coordinate MEK1 in a "face-to-face" orientation. Both MEK1 and BRAF kinase domains exhibit stereotypical inactive conformations, with their regulatory αChelices displaced from their active positions. The N-terminal BRS and RBD domains of BRAF are not clearly defined in the cryo-EM map. A reconstruction filtered to 5Å resolution and contoured at a lower level revealed density adjacent to the CRD that corresponds to the RBD domain (Extended Data Fig. 1g ) but did not provide sufficient detail to allow positioning of an RBD model.
The 14-3-3 dimer organizes inactive BRAF
Our BRAF complexes contain an approximately equimolar ratio of the ε and ζ isoforms (Extended Data Fig. 1a ), and we expect that each side of the 14-3-3 dimer is a mixture of the two isoforms in our reconstructions. For simplicity and convenience, our model is constructed using the Spodoptera frugiperda 14-3-3ζ sequence for both subunits, but with residue numbering corresponding to the human 14-3-3ζ isoform. The 14-3-3 dimer interacts with every ordered domain of BRAF, and interacting residues are highly conserved across all 14-3-3 isoforms (Extended Data Fig. 2a) . The most N-terminal portion of BRAF that is well defined in the cryo-EM maps is the CRD domain. The ~50 residue CRD domain fold contains a small β-sheet and is stabilized by two zinc coordination sites (Fig. 1c ). The domain binds in the center of the 14-3-3 cradle, with contacts to both subunits of the dimer (Extended Data Fig. 2b ). Interestingly, two loops of the CRD domain that are expected to mediate association of the domain with the membrane 17, 19, 20 (residues 239-245 and 253-260) make extensive contact with the 14-3-3 domain in the autoinhibited complex (Extended Data Fig. 3a ). Prior mutagenesis studies with the CRAF CRD have identified two residues in this region that are important for binding to 14-3-3 21 . The corresponding residues in BRAF (R239 and T241) are indeed found at the interface with the 14-3-3 domain (Extended Data Fig. 3a ).
The poorly conserved linker connecting the CRD domain and CR2 region is not visible in our map, but the phosphorylated CR2 segment is well-defined in the phosphopeptide recognition groove on one side of the 14-3-3 dimer (Extended Data Fig. 3b ). The ordered CR2 segment extends from Q359 to I371, with pS365 roughly at its center. Beyond I371, the linker that connects CR2 to the kinase domain is not visible. The BRAF kinase C-lobe contacts both 14-3-3 subunits but interacts most extensively with the pS365-binding subunit, packing against its α9 helix and α8-α9 loop (Extended Data Fig. 3c ). This portion of the 14-3-3 domain also contacts H510 and adjacent residues in the N-terminal lobe of the kinase domain. We observe continuous density connecting the C-terminus of the BRAF kinase domain with the pS729 14-3-3 binding motif, which occupies the recognition groove on the opposite side of the 14-3-3 dimer (Extended Data Fig. 3d,e ). BRAF residues S732-A736 thread between the CRD and 14-3-3 domain as they exit the recognition groove and weak density for a few additional residues indicates that the BRAF C-terminus passes across a hydrophobic surface on the CRD domain before it becomes substantially disordered. The interactions of the 14-3-3 domain with the CR2 segment in the present structure are similar to those observed in a crystal structure of human 14-3-3ζ in complex with a CRAF peptide 22 (Extended Data Fig. 3f ).
The autoinhibited BRAF/MEK kinase module
The BRAF and MEK1 kinase domains bind with their active site clefts juxtaposed, and both kinases exhibit inactive conformations ( Fig. 2a ). Density for ATP-γS is visible in the BRAF active site cleft (Extended Data Fig. 4a ). There is also density for bound nucleotide in the MEK active site that appears to be ADP (Extended Data Fig. 4b ). The inactive conformation of MEK1 and the face-to-face kinase orientation seen here is similar to that previously observed for the isolated kinase domains of BRAF and MEK1 14 . However, the BRAF kinase domain in the prior structure adopted an active but nucleotide-free conformation, as compared with the inactive, nucleotide-bound state in the present structure (Extended Data Fig. 4c,d ). BRAF coordinates MEK1 via an extensive interface involving primarily the Clobes of both kinases, including the kinase activation segments, which interact in an antiparallel manner (Extended Data Fig. 4e , f).
In the BRAF kinase domain, the outward inactive position of the αC-helix is enforced by residues 598-602 in the activation segment, which form a helix-like turn that we refer to as the "inhibitory turn" (Fig. 2b) . The inhibitory turn packs together with hydrophobic residues in the glycine-rich loop, C-helix, and β3 strand to stabilize the inactive state. This inhibitory arrangement resembles that observed in the inactive states of other kinases including CDK2, Src, and EGFR. A superficially similar configuration has been observed in crystal structures of the BRAF kinase domain crystallized with sulfonamide-class inhibitors 23 , but direct comparison with the present structure reveals marked differences in the activation segment and in the relative orientation of the N-and C-lobes of the kinase domain (Extended Data Fig. 4g ,h). The inhibitor-bound conformation is ~15° more open as compared with the nucleotide-bound inactive state observed in the present structure. This difference prompted us to systematically examine the relative N-and C-lobe orientation in more than 50 BRAF kinase structures available in the Protein Data Bank. Strikingly, all previous BRAF kinase structures, none of which contain ATP or an ATP analog, exhibit a markedly more open active site cleft (due to N-lobe rotations of 8-17°) as compared with the autoinhibited, nucleotide-bound structure described here (Extended Data Fig. 4i ,j).
We also obtained a higher resolution view of the autoinhibited BRAF kinase domain by coexpressing it with full-length MEK1 AA in insect cells and crystallizing the purified complex in the presence of GDC-0623 and ATP analog AMP-PNP (Extended Data Fig. 5a ). The resulting 2.6 Å crystal structure superimposes closely on the corresponding portion of the autoinhibited BRAF WT /MEK1 AA /14-3-3 cryo-EM structure (r.m.s.d. 0.56 Å, Extended Data Fig. 5b ), and the regions of interest discussed above are highly similar. The crystal structure reveals in detail interactions that stabilize the inhibitory turn in the BRAF kinase domain (Fig. 2c ), and interactions with the bound nucleotide (Extended Data Fig. 5c ). Strikingly, oncogenic mutations in the BRAF kinase domain cluster in a small region containing both the inhibitory turn and nucleotide-binding residues (Fig. 2d ). Considering the extent of interactions with nucleotide and the unique N-lobe orientation observed in both the cryo-EM and the crystal structure, we hypothesize that ATP binding is an essential feature of the autoinhibited state. Interestingly, we also observe a hydrogen bond between MEK1 residue E102 and the ribose group of the AMP-PNP bound to the BRAF kinase domain (Extended Data Fig. 5d ).
The MEK1 portion of the crystal structure includes an N-terminal helix that is the site of rare activating mutations in cancer and in a "RASopathy" known as cardio-cutaneo-facial syndrome, a genetic developmental disorder stemming from aberrant MAP kinase pathway signaling 24 . This α-helix packs across the back of the N-lobe (Extended Data Fig. 5b ,e), apparently contributing to the stability of the inactive αC-out conformation of MEK, as seen in previous work 25 . For reasons we do not understand, this helix is not resolved in the cryo-EM map of the autoinhibited complex.
Inhibitory mechanisms of the 14-3-3 dimer
The crystal structure described above shows that the MEK1 and the BRAF kinase domains can adopt their mutually inhibited conformations absent any interactions with the 14-3-3 protein. This raises the question of the role of the 14-3-3 dimer in BRAF inhibition. Our structure suggests that rather than inducing an inactive conformation in the kinase domain, the 14-3-3 maintains the inhibited state by sterically blocking formation of the BRAF kinase domain dimer that is required for BRAF activation 11 . In the autoinhibited cryo-EM structure, the surface corresponding to the BRAF dimer interface is obstructed by the bound 14-3-3 dimer ( Fig. 3 , a-c). In particular, dimer interface residues H510, D565, and Y566 are all in contact with the 14-3-3 domain in the autoinhibited structure. Additionally, the 14-3-3 domain sequesters the CRD domain, which is crucial for Ras-driven activation and membrane recruitment of BRAF. In the autoinhibited complex, the surface corresponding to the membrane-binding loops of the CRD is largely occluded in the autoinhibited complex ( Fig. 3d ).
The overall architecture of autoinhibited BRAF is likely shared with both ARAF and CRAF, as key interdomain contacts are highly conserved (Extended Data Fig. 6 ). Consistent with our structural findings, early structure-function studies established a key role for the CRD in maintaining RAF in an autoinhibited state 21, 26 . An alanine scanning mutagenesis study of the CRAF CRD domain identified mutations in 11 surface exposed residues that increased RAS(G12V)-dependent activation of CRAF, including two that fully activated CRAF in the absence of mutant RAS 27 . All 11 of the corresponding residues in BRAF are located at interdomain contacts in the present structure (Extended Data Fig. 2b ). Perhaps most compellingly, the BRAF CRD domain is a hot-spot for germline mutations that cause Noonan Syndrome and related RASopathies 28 . Altered residues map to sites of contact with the 14-3-3 or kinase domain in the present structure, providing a structural rationale for their activating effects (Extended Data Fig. 3g ).
Structures of active BRAF complexes
The autoinhibited structure described above reveals a clear role for phosphorylation of both S365 and S729 in RAF autoinhibition. To further explore the role of these modifications in RAF regulation, we prepared S365A, S729A, and S365A/S729A BRAF variants and expressed them with or without co-expression of MEK1 in insect cells. While we obtained soluble, stable BRAF/MEK1/14-3-3 complexes with BRAF S365A (Extended Data Fig. 7a ), expression experiments with BRAF S729A and BRAF S365A/S729A yielded little BRAF that was largely aggregated and did not co-purify with 14-3-3 proteins (data not shown). Sizeexclusion chromatography of the BRAF S365A sample revealed a broad peak containing BRAF S365A , MEK1 AA , and the 14-3-3 dimer. Examination of the phosphorylation state of the BRAF S365A in this peak revealed near stoichiometric phosphorylation of S729, but little phosphorylation of activation segment sites T599 and S602 (Extended Data Fig. 1c ). Nevertheless, the purified complex was highly active in MEK phosphorylation assays ( Figure 4a , Extended Data Fig. 7a ), and cryo-EM imaging of the complex revealed 2D class averages consistent with larger, dimeric complexes (Extended Data Fig. 8a) .
A three-dimensional reconstruction at ~5 Å resolution of the predominant species in this BRAF S365A /MEK1/14-3-3 sample revealed an active, back-to-back BRAF kinase dimer, with MEK1 bound to each BRAF kinase domain ( Fig. 4b , Extended Data Fig. 8b ). A single 14-3-3 dimer bridges the phosphorylated pS729 sites at the C-termini of the two BRAF kinase domains. We do not observe interpretable density for BRAF regions preceding the kinase domain, nor for the C-terminus beyond S734. We built a model into this cryo-EM map by domain-wise rigid body fitting of the previously reported active MEK/BRAF kinase domain complex (PDB ID 4MNE) and the 14-3-3 dimer from the autoinhibited complex described here. The BRAF/MEK kinase domain portion of the structure exhibits the same overall organization as the prior structures, and inspection of the cryo-EM map confirms that the BRAF C-helix is in its inward position as expected for the active dimer.
Three dimensional classification of particles from the same set of images allowed reconstruction of a second particle similar to the one described above, but with only a single MEK1 bound to the BRAF dimer ( Fig. 4c ). In this "MEK-lite" complex, the 14-3-3 dimer cants to the side of the missing MEK, assuming a more asymmetric position with respect to the back-to-back BRAF kinase domain dimer.
We also expressed wild-type BRAF alone (without MEK co-expression) in both insect and mammalian (HEK293) cells and obtained soluble BRAF in complex with endogenous 14-3-3 proteins using both expression systems (Extended Data Fig. 7 , b-f). Mass spectrometry-based quantitation of phosphorylation in elution fractions revealed nearstoichiometric phosphorylation of S729 and a high level of S365 phosphorylation in peak fractions, but negligible phosphorylation of both T599 and S602 in both mammalian and insect-cell produced BRAF (Extended Data Fig. 8c-f ). The BRAF/14-3-3 complex was highly active in a MEK phosphorylation assay ( Fig. 4a , Extended Data Fig. 7b ).
Cryo-EM imaging of the mammalian-expressed complex revealed predominant 2D class averages consistent with a 14-3-3-bound BRAF dimer, as did imaging of the same sample supplemented with RAF inhibitor GDC-0879 (Extended Data Fig. 8g ). We obtained a 3D reconstruction of the inhibitor-bound BRAF/14-3-3 complex at a nominal resolution of 7 Å, which confirmed the dimeric state of the complex (Extended Data Fig. 8h ,i). As with the MEK-bound dimer, the BRAF kinase domain forms the expected symmetrical, back-to-back dimer in this structure and we do not observe the N-terminal domains of BRAF. Despite the fact that the 14-3-3 dimer bridges the pS729 sites of the two kinase domains, it adopts a highly asymmetric position with respect to the kinase dimer (Extended Data Fig. 8i ). In this skewed position, the 14-3-3 dimer approaches the active site cleft and intrudes into the MEK-binding region of one BRAF kinase domain, but not the other.
Discussion
In the quiescent state, BRAF, MEK1, and a 14-3-3 dimer form a tightly integrated signaling device. In light of their extensive interactions, we propose that the RAF/MEK/14-3-3 complex, rather than RAF per se, serves as the RAS-activated switch that initiates signaling through the MAP kinase cascade. Phosphorylation of both 14-3-3 binding sites and engagement by a 14-3-3 dimer is required for maturation of RAF into its regulated, inactive state. Our structural and biochemical findings argue that MEK also contributes to the stability of the inactive state of BRAF, but we do not exclude the possibility that RAFs can assemble into an autoinhibited 14-3-3 complex without MEK. The essential role of pS729 in both the autoinhibited and active states of the kinase and its stoichiometric phosphorylation in our purified complexes leads us to suggest that this site is a structural phosphorylation required for proper assembly and regulation of BRAF complexes. Of note, phosphorylation on T599 and S602 is widely thought to play a crucial role in BRAF activation 29 , but we find little to no phosphorylation on these sites in active BRAF/14-3-3 dimers. The potential role of activation loop phosphorylation in RAF regulation merits further study.
The structures described here provide views of RAF in its quiescent and activate states and in light of prior functional dissection of RAF regulation, they outline a model for RAF activation (Extended Data Fig. 9 ). In the autoinhibited state, the RBD is exposed, allowing recruitment of the quiescent complex to the membrane by activated RAS. In contrast, the CRD and its membrane binding surface is largely buried by interactions with the 14-3-3 dimer and other segments of RAF, suggesting that its "extraction" upon RAS binding and membrane localization is the key event promoting release of the inhibitory position of the 14-3-3 domain. Released from its inhibitory position, the 14-3-3 dimer can rearrange to bridge the pS729 sites in the C-terminal tails of two BRAFs, driving formation of the active BRAF dimer. Once activated, BRAF can phosphorylate MEK, promoting its release 14 . Steric effects of the 14-3-3 domain could also modulate affinity for MEK, as evidenced by the asymmetric position it assumes upon MEK release.
The inactive-state structures described here reveal the bona fide inactive conformation of BRAF and thereby provide a structural foundation for understanding its activation by mutations in cancer. Oncogenic mutations in V600 and K601 in the inhibitory turn are not compatible with the structural context of these residues, providing a rationale for their activating effect via destabilization of the inhibitory turn ( Fig. 2c ). Other less common oncogenic BRAF mutations occur in residues that participate directly in coordination of ATP and its associated divalent cation (Fig. 2d ), and they may destabilize the autoinhibited state by weakening interactions with ATP and/or by disrupting interactions of the glycine-rich loop with the inhibitory turn in the activation segment. Many of the same BRAF residues are also altered in RASopathies 28 (Extended Data Fig. 5f ). Outside the kinase domain, somatic point mutations in or near the CR2 phosphorylation site occur in CRAF and ARAF in diverse cancers including lung adenocarcinoma 30 . These mutations ablate the CR2 14-3-3 binding site, promoting formation of the active RAF dimer as we observe here with the BRAF S365A mutant. The KIAA1549:BRAF truncation/fusion oncoprotein found in pediatric low-grade gliomas lacks the entire CR1 and CR2 regions of BRAF, and is therefore constitutively active 31 .
The integral nature of the RAF/MEK/14-3-3 switch has important pharmacologic implications. It is well established that certain MEK and RAF inhibitors can stabilize or destabilize their interaction 14, [32] [33] [34] . However, the notion that the RAF/MEK/14-3-3 complex, distinct from the isolated RAF and MEK kinases, may represent a relevant pharmacologic receptor for a broader range of inhibitors has not, to our knowledge, been systematically explored. Arguably the most perplexing aspect of RAF inhibitor pharmacology is the paradoxical activation of the MAP kinase pathway by certain RAF kinase inhibitors 4, 35, 36 . Diverse RAF inhibitors disrupt autoinhibitory interactions of the BRAF kinase with its N-terminal region 37 , and some promote dimerization of the isolated BRAF kinase domain 23 . Considering the extensive interactions of BRAF with ATP in the autoinhibited state, we speculate that RAF inhibitors may promote conformational activation by displacing ATP from quiescent RAF. Whether this leads to observed paradoxical pathway activation will in turn depend upon ensuing cellular events, potentially including changes in RAF phosphorylation state, RAS-binding, membrane localization and 14-3-3 rearrangements, and on the potency of a particular agent as an inhibitor of activated RAF dimers.
Many questions regarding RAF regulation remain. The structures described here and the ability to prepare full-length autoregulated and active BRAF will inform and enable detailed mechanistic studies of RAF activation and inhibitor pharmacology. In the long term, a deeper understanding of RAF regulation should aid in development of more effective and better tolerated therapeutics for RAF-driven cancers. insect-cell derived 14-3-3ε and 14-3-3ζ.
Preparation of BRAF/MEK/14-3-3 complexes from insect cells (Sf9).
Recombinant baculovirus expressing full length human MEK1 (either wild type or S218A/ S222A) fused with an N-terminal His 6 -tag was prepared using baculoviral transfer vector pAc8. BRAF/MEK1/14-3-3 complexes (either wild type or with the desired BRAF and/or MEK mutants) were prepared by co-expression in insect cells using separate baculoviruses for MEK1 and BRAF. Liter-scale cultures (4 L total for a typical preparation) were coinfected with high-titer viral stocks expressing the desired BRAF and MEK1 variants at a 1:1.5 ratio (by volume, 1% culture volumes of BRAF virus, 1.5% of MEK1), and cells were harvested by centrifugation 65-72 h post-infection. BRAF/MEK/14-3-3 complexes were purified from cell pellets as described above for BRAF/14-3-3 complexes, but all buffers were supplemented with MEK inhibitor GDC-0623 to a final concentration of 2 μM. As with BRAF alone, co-expressed BRAF and MEK1 co-purified with insect-cell derived 14-3-3 ε and ζ.
Preparation of the BRAF/14-3-3 complex from mammalian cells (HEK293)
Full-length human BRAF bearing an N-terminal His 8 -tag and a C-terminal StrepII tag was cloned into pcDNA™5/FRT/TO vector. For protein production, liter-scale suspension cultures (2L total for a typical preparation) of HEK293 cells (Expi293F, ThermoFisher Scientific) were transfected using Expi293™ expression system according to the manufacturer's protocol (ThermoFisher Scientific). Cells were harvested by centrifugation 48-60 h post-transfection. BRAF/14-3-3 complexes were purified from mammalian cell pellets as described above for isolation BRAF/14-3-3 from insect cells. Analysis of the purified sample by SDS-PAGE revealed that BRAF co-purified with mammalian cellderived 14-3-3 isoforms.
Preparation of Spycatcher-MEK1 from insect cells (Hi5)
We prepared kinase-dead MEK1 (fused to Spycatcher to alter its electrophoretic mobility) for use as a substrate in in vitro BRAF activity assays. 
Size-exclusion chromatography with multiangle light scattering (SEC-MALS).
The BRAF WT /MEK1 AA /14-3-3 complex was applied to a Superdex 200 10/300 GL column (GE Healthcare) in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 0.5 mM TCEP, 10 μM ATP-γS, 2 μM GDC-0623. In-line multi-angle light scattering analysis was performed with an OptiLab rEX refractive index detector followed by a miniDAWN TREOS light scattering detector, and data were analyzed with ASTRA (Wyatt Technology).
Kinase activity assay.
BRAF activity in SEC elution fractions was measured by diluting an aliquot of each fraction five-fold, and adding 1 μl of the diluted sample to 14 μl of a reaction mixture containing assay buffer (50 mM Tris pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 0.5 mM TCEP, and 1 mM sodium vanadate) supplemented with 2.67 μM Spycatcher-MEK1 D190N as a substrate. Kinase reactions were started by addition of 5 μl of 4 mM ATP in assay buffer. After incubation for 20 minutes at 25°C, reactions were stopped by addition of SDS-PAGE sample buffer and heating to 95°C. Reaction products were resolved on a Novex™ 12% Tris-Glycine Midi gel (Invitrogen), and subsequently western blotted with anti-phosphoMEK1/2(S218/222) antibody (Cell Signaling Technology) to detect phosphorylation of the ~55 kDa Spycatcher-MEK substrate.
Time-course kinase assays of BRAF WT /MEK AA /14-3-3, BRAF S365A /MEK AA /14-3-3 and BRAF WT /14-3-3 samples were performed using the same reaction buffer and substrate concentrations described above, but each sample was diluted to 100 nM, and 20 μl was used in a final reaction volume of 200 μl (final enzyme concentration was 10 nM in the reaction mixture). After initiating the assay by addition of ATP, 20 μl aliquots were removed from the reaction at the designated time points and stopped by mixing with an equal volume of 5X SDS-PAGE sample buffer and heating to 95°C. Reaction products were analyzed by SDS-PAGE and western blotting for phosphoMEK1/2 as described above.
Pull-down assay for 14-3-3 association.
Recombinant baculoviruses expressing full-length human 14-3-3 β/α, γ, δ/ζ or ε and bearing an N-terminal Flag-tag were prepared using baculoviral transfer vector pAc8. BRAF WT and MEK AA were co-expressed with each of the four different human 14-3-3 isoforms in insect cells by co-infection. 100 ml of co-infected Sf9 cells were harvested 55-65 h post-infection, lysed in lysis buffer, then parallel aliquots of clarified lysate were applied to Strep-Tactin®XT magnetic beads (IBA GmbH) or Anti-DYKDDDDK magnetic Agarose (anti-FLAG, Pierce™). After washing beads with lysis buffer, bound proteins were eluted with SDS-PAGE sample buffer and resolved on 8% Bis-Tris PAGE gels. Parallel gels were western blotted using anti-14-3-3 (pan) and anti-Flag antibodies (Cell Signaling Technology).
Cryo-EM data acquisition and processing.
BRAF WT /MEK1 AA /14-3-3 complex in SEC buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 0.5 mM TCEP, 10 μM ATP-γS, 2 μM GDC-0623) was applied to glowdischarged holey carbon grids (Quantifoil R1.2/1.3, 400 mesh) and vitrified using a FEI Vitrobot Mark IV. Frozen hydrated samples were imaged on an FEI Titan Krios at 300 kV with a Gatan Quantum Image Filter with K2 Summit direct detection camera in superresolution mode with a total exposure dose of ~50 electrons. 35 frames per movie were collected at a magnification of 130,000×, corresponding to 0.53 Å per pixel. In total, 8440 micrographs were collected at defocus values ranging from −1.8 to −3.3 μm from two data collections of 4097 and 4343 images (of which 1628 images in the later collection were tilted by 25° in an attempt to increase observed orientations). The movie frames were motion-corrected and dose-weighted by MotionCor2 39 , downsampled to 1.06 Å per pixel and CTF parameters were estimated by CTFFIND4 40 . Particle picking was carried out using crYOLO 41 and template based particle picking within Relion 42 giving 3,531,955 initial particles. Following successive rounds of 2D and 3D classification 427,592 particles were selected. Additional two rounds of 3D classification led to the final reconstruction of 4.1 Å from 165,298 particles. Per particle motion correction "particle polishing" alongside per particle CTF refinement was trialed with no improvement in resolution or map quality. Maps used for figures were filtered according to local resolution with b-factor sharpening within Relion 42 . Models were fit into the map using Coot 43 and further refined with PHENIX 44 and REFMAC5 45 . Statistics for the final refinement are presented in Extended Data Table 1 .
BRAF S365A /MEK1 AA /14-3-3 complex in SEC buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 0.5 mM TCEP, 10 μM ATP-γS, 2 μM GDC-0623) was applied to glow-discharged holey carbon grids (Quantifoil R1.2/1.3, 400 mesh) and vitrified using a Leica EM GP. Frozen hydrated samples were imaged on an FEI Talos Arctica at 200 kV with K3 Summit direct detection camera in counting mode with a total exposure dose of ~50 electrons. 42 frames per movie were collected at a magnification of 36,000×, corresponding to 1.11 Å per pixel. 3146 micrographs were collected at defocus values ranging from −2.0 to −3.0 μm. Initial particle picking was carried with crYOLO 41 and ab-initio models were generated in cryoSPARC 46 showing two distinct classes, one showing back-to-back BRAF kinase dimer, with MEK1 bound to each BRAF kinase domain, while the other only had a single MEK1 bound ("MEK-lite"). All following steps were carried out within Relion 42 . Reference based picking resulted 2,008,323 particles. Following 2D classification 1,441,851 particles were subjected to a guided 3D classification using single copies of the dimeric and "MEK-lite" as reference models. 705,222 dimer particles were then subjected to a further round of standard 3D classification leaving 425,135 particles. Following Bayesian polishing and 3D refinement this resulted in a reconstruction of 4.9 Å. In addition, 736,629 particles were identified as "MEK-lite" and following further 3D classification 595,672 particles were subjected to Bayesian polishing and 3D refinement resulting in a 5.7 Å reconstruction. Models were built for both reconstructions by rigid-body fitting the BRAF and MEK1 kinase domains from PDB entry 4MNE using Coot 43 . The 14-3-3 domain was modeled by rigid-body fitting of the insect cell 14-3-3 zeta domain from the autoinhibited BRAF/MEK/ 14-3-3 structure described here; each subunit of the 14-3-3 dimer was fit independently. Cterminal pS729 tails were manually built for each structure, with reliance on the autoinhibited structure for placement of pS729. For both reconstructions, cryo-EM maps were deposited in the Electron Microscopy Data Bank and polyalanine models were deposited in the Protein Data Bank. Data collection and image processing statistics for both structures are presented in Extended Data Table 1 .
The mammalian cell-produced BRAF WT /14-3-3 complex in SEC buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 0.5 mM TCEP, 10 μM ATP-γS, 2 μM GDC-0623) with/without 1μM GDC-0879 was applied to glow-discharged holey carbon grids (Quantifoil R1.2/1.3, 400 mesh) and vitrified using a Leica EM GP. Frozen hydrated samples were imaged on an FEI Titan Krios at 300 kV with a Gatan Quantum Image Filter with K3 Summit direct detection camera in counting mode with a total exposure dose of ~70 electrons. 50 frames per movie were collected at a magnification of 105,000×, corresponding to 0.85 Å per pixel. 4002 and 4418 micrographs per sample (with and without 1μM GDC-0879) were collected at defocus values ranging from −1.7 to −2.7 μm. The movies were downsampled to 1.7 Å and particle picking was carried out on the GDC-0879 sample with crYOLO 41 giving 365,083 particles. Following two rounds of 2D classification 234,539 particles remained. Two further rounds of 3D classification within Relion 42 , using an initial model derived from cryoSPARC 46 , resulted in 66,215 particles leading to a 6.8 Å reconstruction after 3D refinement. The BRAF WT /14-3-3 model was constructed by rigidbody fitting the BRAF and MEK1 kinase domains from PDB entry 4MNE using Coot 43 . The 14-3-3 domain was modeled by rigid-body fitting of the human 14-3-3 zeta domain (PDB Entry 3NKX). Each subunit of the 14-3-3 dimer was fit independently, and the Cterminal pS729 tails were manually built. The cryo-EM map has been deposited in the Electron Microscopy Data Bank and the polyalanine model has been deposited in the Protein 
Author Manuscript
Author Manuscript
Author Manuscript Data Bank. Data collection and image processing statistics for this structure are presented in Extended Data Table 1 .
Expression and purification of the BRAF/MEK kinase domain complex.
For insect cell expression of the BRAF kinase domain in complex with MEK1, two recombinant baculovirus species were employed. The first was prepared using baculoviral transfer vector pFastBac Dual and encoded the BRAF kinase domain (BRAF residues 445-723, fused to an N-terminal His 6 
BRAF/MEK kinase domain crystallization and structure determination.
For crystallization, an aliquot of the BRAF/MEK kinase complex was incubated with 5 mM MgCl 2 , 2 mM Adenosine 5′-(β,γ-imido)triphosphate (AMPPNP), and 0.2 mM GDC-0623 in storage buffer at 4°C overnight. Rod-shaped crystals suitable for structure determination were obtained by vapor diffusion in hanging drops using a reservoir solution consisting of 100 mM Bis-Tris pH 6.5, 200 mM ammonium sulfate, and 22% PEG 3350 at room temperature. Crystals were harvested and flash frozen in liquid nitrogen using additional 20% glycerol as a cryoprotectant. X-ray diffraction data were collected at 100 K using NE-CAT beamline ID-24-C at the Advance Photon Source, Argonne National Laboratory, at a wavelength of 0.979 Å. Data were integrated and merged using XDS 47 and scaled using Aimless in the CCP4 suite 48 . The structure was phased by molecular replacement in PHASER 49 using the relevant domains of the autoinhibited cryo-EM structure and PDB entry 4MNE as initial search models. GDC-0623 was placed into positive density in an initial F o -F c map and included in subsequent rounds of refinement using PHENIX.REFINE 50 . Successive manual refinement was performed using COOT 43 . The structure was refined to R work /R free values of 0.22/0.25 at a resolution of 2.58 Å. Data collection and refinement statistics are presented in Extended Data Figure 5a .
Mass spectrometry analysis.
BRAF complexes were digested separately with trypsin and Lys-C, desalted by C18, dried by vacuum centrifugation, and analyzed in triplicate by CE-MS using a ZipChip autosampler and CE instrument (908 Devices, Boston, MA) interfaced to a QExactive HF mass spectrometer (ThermoFisher Scientific, Waltham, MA). Peptides were loaded for 20 seconds on an HR chip and electrophoresis performed at 700 V/cm for 10 minutes, with pressure assist activated at 1 min. To identify BRAF phosphopeptides, digests were analyzed by data-dependent MS/MS. The five most abundant ions in each MS scan (60K resolution) were subjected to MS/MS (15K resolution, 30% collision energy). Dynamic exclusion was activated with a repeat count of 1 and an exclusion duration of 6 seconds. MS/MS spectra were converted to .mgf format using multiplierz software 51, 52 , and searched against a database of BRAF using Mascot 2.6.1. Search parameters specified trypsin or Lys-C specificity with up to two missed cleavages, variable oxidation of methionine, variable phosphorylation of serine, threonine, or tyrosine, fixed carbamidomethylation of cysteine, and precursor and product ion tolerances of 10 ppm and 25 mmu, respectively. Identified sites of phosphorylation were confirmed using mzStudio software 53 . In experiments to determine stoichiometry of phosphorylation, digests were analyzed by CE-MS (MS1 scans with 15K resolution), with precursor peak areas used for quantification according to the following equations: % phosphorylation = corrected phosphopeptide peak area total peptide peak area (1) total peptide peak area = corrected phosphopeptide peak area + nonphosphopeptide peak area (2) corrected phosphopeptide peak area = phosphopeptide peak area × correction factor for ionization efficiency (3) Correction factors for ionization efficiency were determined in separate experiments using either BRAF protein digests or synthetic BRAF peptide standards. Peptides were treated +/− alkaline phosphatase (pptase) and analyzed in triplicate by CE-MS as described above. After normalizing for loading amounts (using non-phosphorylatable BRAF peptides VFLPNK and LIDIAR for BRAF digests or a spiked standard peptide for BRAF synthetics), correction factors were calculated according to:
correction factor = peak area nonphosphorylated peptide +pptase − peak area nonphosphorylated peptide −pptase peak area phosphopeptide −pptase (4) Because discovery experiments did not detect phosphorylation of MEK1 activation loop sites 218/222 (peptide 206 LCDFGVSGQLIDSMANSFVGTR 227 ) we estimated an upper bound of phosphorylation of these residues by analyzing digests +/− pptase treatment as above.
In these experiments, we used targeted SIM scans of 206 LCDFGVSGQLIDSMANSFVGTR 227 and normalization peptides, and then calculated MEK1 activation loop phosphorylation as: 
Author Manuscript
Author Manuscript % phosphorylation = 1 − Nonphosphorylated MEK peptide peak area −pptase Nonphosphorylated MEK peptide peak area +pptase (5) Data analysis and peak integration were performed using mzStudio software 53 .
To identify 14-3-3 proteins, MS/MS spectra from data-dependent CE-MS analyses of trypsin and Lys-C digested BRAF complexes were converted to .mgf format using multiplierz software 51, 52 , and searched against a forward-reverse human protein database (uniprot) with Mascot 2.6.1 (same search parameters described above). Data were filtered to ~1% FDR, and peptide sequences mapped to genes using the multiplierz pep2gene tool 52 .
Sequence alignments.
For Extended Data Figs. 2a and 6 , sequences were aligned using ClustalW and figures were prepared with ESPript 3.0 54 .
Structural biology applications used in this project were compiled and configured by SBGrid 55 .
Extended Data
Extended Data Table 1 .
Cryo-EM data collection, refinement and validation statistics. isoforms, BRAF preferentially associated with the endogenous insect cell 14-3-3 proteins (as seen in the Strep-TactinXT-precipitated lanes of the Coomassie-stained gel). c, Mass spectrometry-based quantitation of selected phosphorylation sites in wild type and S365A BRAF complexes purified for structural analysis. d, Portion of a representative micrograph used for the autoinhibited BRAF/MEK1 AA /14-3-3 reconstruction described here. e, Representative 2D class averages for the autoinhibited BRAF/MEK1 AA /14-3-3 reconstruction. Scale bar is 10 nm. f, Fourier shell correlation (FSC) curves for the reconstruction. The horizontal line indicates a correlation of 0.143; the FSC curve for two half-maps (blue) the crosses this threshold at a resolution of 4.1Å. A correlation curve for the map versus the atomic model is plotted in red. g, The autoinhibited BRAF/MEK1 AA / 14-3-3 cryo-EM map filtered to 5 Å resolution and contoured at a lower level to reveal weaker density corresponding to the RBD domain. Map surface is colored by domain as in Fig. 1 in the main text. Unassigned densities (gray) can be ascribed to the RBD domain and other poorly structured elements as indicated. For gel source data, see Supplementary Figure  1 . Experiments in panels a and b were repeated at least twice with similar results. Imaging experiments in d and e were repeated 4 times with similar results. a, Sequence alignment of insect cell (Spodoptera frugiperda) and human 14-3-3 isoforms.
Secondary structure is indicated above the alignment. Identically conserved residues are shaded red. Symbols above the alignment indicate contacts with the BRAF CRD domain (violet squares), kinase domain (blue triangles), and pS365 or pS729 segments (black circles). b, Interactions of the CRD domain. Domains contacting the CRD are shown with a transparent surface and the CRD domain is shown as a violet ribbon with gray spheres representing bound zinc atoms. Sidechains are shown for CRD residues that correspond to 7 (of 11 total) residues identified in an alanine scanning mutagenesis study of the CRAF CRD domain 27 . Alanine mutations in the corresponding residues increased RAS(G12V)dependent activation of CRAF. Two mutations in this study fully activated CRAF in the absence of RAS(G12V); the corresponding BRAF residues are F247 and D249. F247 makes hydrophobic contacts with both the kinase C-lobe and the 14-3-3 domain, while D249 is crystal structure (shown in blue and cyan), revealing a close correspondence in conformations of the bound peptides. g, The BRAF CRD is a hotspot for RASopathy mutations, which map to sites of contact between the CRD (purple), kinase (blue), and 14-3-3 domains (tan), and are expected to destabilize the autoinhibited assembly. Sites of RASopathy mutations are shown in stick form and labeled. RASopathy mutations in the BRAF kinase domain (Q709) and CR2 region (red, S365) are also expected to destabilize these inhibitory intramolecular contacts. . Note that the present structure (dark blue, with C-helix colored purple and the activation segment orange) exhibits key features of an autoinhibited state (C-helix out, with an inhibitory turn in the activation segment), whereas the prior structure (light blue) adopts an overall active conformation. e, Detailed view of a portion of the C-lobe contact between BRAF (blue) and MEK1 (green). f, Portions of the BRAF (blue) and MEK1 (green) activation segments interact in an anti-parallel orientation. Activating phosphorylation sites in the MEK1 activation loop are substituted with alanine in this structure (S218A, S222A), but neither residue is positioned appropriately for phosphorylation by BRAF. Note that our discussion of these interactions relies in part on the crystal structures referenced to build the atomic model, as the cryo-EM map in this region does not unambiguously define all sidechain conformations. g-j, Comparison of BRAF kinase domain conformations and relative N-and C-lobe orientations. g, Sulfonamidecontaining BRAF inhibitors perturb the inactive conformation of BRAF. The BRAF kinase domain in the present structure (blue ribbon, with C-helix colored red and the activation segment orange) is superimposed on the structure of the BRAF kinase domain crystallized as a monomer with PLX4720 (gray, PDB ID 4WO5). The superposition is based on the Clobes of both kinases, revealing an altered orientation of the N-lobe in the inhibitor-bound structure (a rotation of ~15°). Note also that the inhibitory turn in the activation segment helix is replaced by a short helix in the PLX4720 complex. h, Alternate view of the superposition shown in panel g, highlighting the axis of rotation (pink arrow) between the Nlobes. i, As in panel h, but with a representative inhibitor-bound dimeric BRAF structure superimposed (5CSW, a dabrafenib complex). The rotation axes for N-lobe rotations of dimer structures are shown as green arrows. Note that the orientation of the rotation axis is similar for all of the dimer structures, but almost orthogonal to that of the monomer structure in panel h. In both h and i, the Cα atoms of K522 are shown as spheres as a point of reference. j, Relative N-lobe rotation of WT and V600E BRAF crystal structures available in the Protein Data Bank (PDB) are compared with the present nucleotide-bound, autoinhibited structure. As illustrated in panels h and i, C-lobes of the BRAF kinase domains were superimposed, and the rotation required to bring the kinase N-lobes into register were calculated using PyMol. With the exception of 4MNE, all structures compared were determined in complex with inhibitors. a, Crystallographic data collection and refinement statistics for the structure of the BRAF kinase domain (BRAF KD ) in complex with MEK1 AA , AMPPNP and MEK inhibitor GDC-0623. Data were recorded from a single crystal. b, The autoinhibited BRAF/MEK kinase domain crystal structure is superimposed on the corresponding region of the autoinhibited cryo-EM structure. c, ATP-analog AMPPNP is extensively coordinated in the autoinhibited state. Hydrogen bonds from coordinating residues are indicated by dashed lines. d, MEK1 residue E102 in the β3-αC loop is positioned to form a hydrogen bond with a ribose hydroxyl of the nucleotide bound in the BRAF active site. e, Rare but recurrent oncogenic mutations in MEK1 map to the region of the N-terminal helix. A small, in-frame deletion of two residues (E102/I103) in the β3-αC loop maps to the region of the interface between BRAF and MEK1. f, RASopathy mutations in BRAF illustrated in the inactive conformation of the kinase domain. As with oncogenic mutations in many of the same residues, RASopathy-associated mutations will perturb nucleotide binding and/or the stability of the inhibitory turn. Interestingly, residues E501 and T599 form a hydrogen bond (dashed line) that appears to contribute to the stability of the inhibitory turn. allows isolation of a late-eluting peak (~15 ml) with little MEK-phosphorylation activity that corresponds to the autoinhibited BRAF/MEK1/14-3-3 monomer complex (panel c, fractions B8-C3). d, BRAF WT was expressed in mammalian HEK293 cells, purified by serial Ni-NTA agarose and StrepTrapHP affinity chromatography, and subjected to SEC on Superdex 200. e, Elution fractions from the BRAF WT /14-3-3 SEC run in panel d are analyzed by SDS-PAGE and western blotting, revealing that BRAF co-purifies with endogenous human 14-3-3 proteins. Fractions were also blotted for total BRAF (anti-StrepII), pS365 and pS729. f, Mass spectrometry analysis of trypsin and Lys-C protease digests of peak fractions of the BRAF/14-3-3 complex from HEK293 cells revealed multiple peptide sequences that mapped uniquely to six of the seven human 14-3-3 isoforms. The δ and α isoforms are phosphorylation variants of ζ and β, respectively. For gel source data, see Supplementary  Figure 1 . SEC experiments were repeated at least 3 times (a-e), activity assays 2 (a) and 1 (b, c) times, and blotting 2 times (e) with similar results.
note the high fractional phosphorylation of S729 in all samples, and the negligible phosphorylation of activation segment sites T599 and S602. g, Representative 2D-class averages for BRAF WT /14-3-3 complexes prepared from mammalian cells with (upper row) and without (lower row) addition of BRAF inhibitor GDC-0879 (1 μM). Both samples yielded class averages indicative of the same particle architecture, but those of the drugtreated sample revealed better-defined secondary structure. Scale bar is 10 nm. h, FSC curve for the BRAF WT /14-3-3 reconstruction. i, Single-particle reconstruction of the mammalian cell-produced BRAF WT /14-3-3 complex treated with GDC-0879. The reconstruction reveals a back-to-back BRAF kinase domain dimer with a 14-3-3 dimer bridging between its Cterminal pS729 tails. Comparison of these front and back views reveals the highly asymmetric position of the 14-3-3 dimer with respect to the dimerized kinase domains. Imaging experiments in panels a and g were repeated 2 times with independent preparations with similar results. a, Schematic showing the domain organization of BRAF and MEK1. Key regulatory phosphorylation sites are indicated above the schematics and residue numbers for domain boundaries are shown below. b, Single-particle reconstruction cryo-EM density map derived from imaging of the full-length BRAF/MEK AA /14-3-3 complex, colored according to local resolution. c, Ribbon diagram showing the overall structure of the complex. BRAF and MEK1 domains are colored as in panel a, and the two subunits of the 14-3-3 dimer are shown in orange and tan. Segments of BRAF containing the pS365 and pS729 regulatory sites bind opposite sides of the 14-3-3 dimer, and are shown in red. The CRD domain occupies a central location in the complex, with contacts to both 14-3-3 subunits, both the pS365 and pS729 regulatory segments, and the BRAF kinase domain. Abbreviations: BRS, BRAF-specific domain, which is unique to BRAF; RBD, RAS-binding domain; CRD, cysteine-rich domain. a, BRAF coordinates MEK1 in a face-to-face orientation, with extensive contact between the kinase C-lobes. Both kinases adopt an inactive, αC-out conformation. b, Overall view of the autoinhibited BRAF kinase domain. The C-helix (purple) is propped in an outward, inactive conformation by the inhibitory turn in the activation segment (orange). ATP-γS is bound in the active site cleft. c, Detailed view of the structure and interactions of the inhibitory turn. Residue V600, the most common site of oncogenic mutations, is part of a cluster of hydrophobic residues (yellow) that stabilize this inactive conformation. K601 also stabilizes this configuration; it hydrogen bonds with G596 in the DFG motif and packs with F468 in the glycine-rich loop. d, Oncogenic mutations (red) cluster in the inhibitory turn or residues that coordinate ATP. Panels a and b are drawn from the cryo-EM structure; panels c and d from the crystal structure of the autoinhibited kinase domain complex. a, Surface representation of an active BRAF kinase domain dimer, with interface residues shaded white for one subunit and gray for the opposite subunit (drawn from PDB entry 4MNE). b, Oblique view of the autoinhibited BRAF complex, with BRAF kinase domain residues that contact the α8-α9 loop of the 14-3-3 domain shaded yellow. c, Comparison of the 14-3-3 contact (left panel) and the BRAF dimer interface (center panel). The respective surfaces are overlaid in the right panel, demonstrating that the 14-3-3 interaction will sterically interfere with BRAF kinase dimerization. d, Surface view of the complex in the region of the CRD, with the putative membrane-binding loops of the CRD shaded green. a, Kinase activity assays for autoinhibited and active BRAF complexes. Time course of phosphorylation of an exogenous, kinase-dead MEK1 substrate is measured by western blotting for pS218/222 MEK for the autoinhibited wild-type monomer complex (left panel), the BRAF S365A complex (center panel), and a wild-type BRAF/14-3-3 complex prepared without co-expression of MEK1 in insect cells (right panel). Blots for BRAF (anti-strepII) and MEK are provided as loading controls for enzyme and substrate, respectively. For gel source data, see Supplementary Figure 1 . b, Cryo-EM structure of the active, dimeric BRAF S365A /MEK1 AA /14-3-3 complex. In this active configuration, the 14-3-3 dimer bridges the S729-phosphorylated tails of the back-to-back BRAF dimer (right panel). Portions of BRAF N-terminal to the kinase domain are not visible in the reconstruction. c, The same preparations also contained BRAF S365A /MEK1 AA /14-3-3 complexes containing only one MEK1 subunit. The overall organization of the remaining subunits is closely similar, but the 14-3-3 dimer pivots to the side of the missing MEK. See also Extended Data Fig. 8 . 
